Table 2.
Baseline characteristics of the subjects according to follow-up outcomes
| Variables | Subjects developed HTN (n = 2047) | Subjects did not develop HTN (n = 2639) | p |
|---|---|---|---|
| TyG | 8.55 (8.20–8.92) | 8.23 (7.92–8.59) | < 0.001 |
| Gender (male/female, n) | 1541/506 | 1636/1003 | < 0.001 |
| Age (years) | 44.0 (36.0–54.0) | 38.0 (33.0–46.0) | < 0.001 |
| BMI (kg/m2) | 23.6 (21.8–25.4) | 21.7 (19.8–23.6) | < 0.001 |
| SBP (mmHg) | 124.0 (117.0–131.0) | 112.0 (105.0–120.0) | < 0.001 |
| DBP (mmHg) | 80.0 (75.0–84.0) | 71.0 (67.0–76.0) | < 0.001 |
| WC (cm) | 81.0 (75.0–87.0) | 75.0 (69.0–81.0) | < 0.001 |
| BUN (μmol/L) | 5.09 (4.29–5.96) | 4.86 (4.15–5.66) | < 0.001 |
| Cr (μmol/L) | 74.0 (64.0–83.0) | 71.0 (60.0–80.0) | < 0.001 |
| FPG (mmol/L) | 4.53 (4.21–4.89) | 4.37 (4.09–4.66) | < 0.001 |
| UA (μmol/L) | 342.0 (284.0–395.0) | 306.0 (250.0–364.0) | < 0.001 |
| AST (U/L) | 20.0 (17.0–25.0) | 19.0 (16.0–23.0) | < 0.001 |
| ALT (U/L) | 25.0 (17.0–37.0) | 20.0 (15.0–30.0) | < 0.001 |
| γ-GGT (U/L) | 21.0 (15.0–34.0) | 16.0 (11.0–24.0) | < 0.001 |
| TC (mmol/L) | 4.83 (4.28–5.50) | 4.56 (3.99–5.14) | < 0.001 |
| TG (mmol/L) | 1.38 (1.01–2.02) | 1.07 (0.80–1.51) | < 0.001 |
| HDL-C (mmol/L) | 1.26 (1.07–1.52) | 1.27 (1.08–1.58) | 0.020 |
| LDL-C (mmol/L) | 2.73 (2.24–3.29) | 2.51 (2.04–3.03) | < 0.001 |
| Apo-A1 (g/L) | 1.29 (1.13–1.50) | 1.30 (1.13–1.48) | 0.815 |
| Apo-B (g/L) | 0.97 (0.81–1.14) | 0.85 (0.71–1.01) | < 0.001 |
| eGFR (mL/(min·1.73 m2)) | 108.0 (95.0–122.0) | 111.6 (100.2–126.2) | < 0.001 |